#Market News January 18, 2018 / 1:14 PM / in 12 minutes BRIEF-AzurRx BioPharma Announces Receipt of Required Approvals to Add French Clinical Site for its Phase IIa Study of MS1819-SD Reuters Staff 1 Min Read 
Jan 18 (Reuters) - Azurrx Biopharma Inc: 
* AZURRX BIOPHARMA ANNOUNCES RECEIPT OF REQUIRED APPROVALS TO ADD FRENCH CLINICAL SITE FOR ITS PHASE IIA STUDY OF MS1819-SD FOR EXOCRINE PANCREATIC INSUFFICIENCY 
* AZURRX BIOPHARMA INC - IN PARTNERSHIP WITH MAYOLY SPINDLER, RECEIVED REQUIRED APPROVALS TO ADD A FRENCH SITE TO PHASE IIA STUDY OF MS1819-SD Source text for Eikon: Further company coverage: